Celldex Therapeutics (NASDAQ:CLDX) stated gains of 859,761 shares or 3.6% in the short interest. The short interest registered from 24,139,798 on May 31,2016 to 24,999,559 on June 15,2016. In terms of floated shares, the shorted positions stood at 25.5%. The stock has been averaging 3,032,841 shares daily in trading and would need 8 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.
Celldex Therapeutics (NASDAQ:CLDX): The stock opened at $4.16 on Friday but the bulls could not build on the opening and the stock topped out at $4.49 for the day. The stock traded down to $4.15 during the day, due to lack of any buying support eventually closed down at $4.36 with a loss of -4.60% for the day. The stock had closed at $4.57 on the previous day. The total traded volume was 5,531,378 shares.
The company shares have dropped -81.58% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $28.08 and the one year low was seen on Mar 17, 2016. The 50-Day Moving Average price is $4.21 and the 200 Day Moving Average price is recorded at $7.06.
Celldex Therapeutics (NASDAQ:CLDX) has climbed 2.11% in the past week and advanced 0.69% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 3.8% and the outperformance has advanced to 3.74% for the last 4 weeks period.
Celldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.